Selexipag

Category: Blood Pressure



Selexipag Overview

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[1] ACT-333679 or MRE-269, the active metabolite of selexipag Contents 1 Contraindications 2 Adverse effects 3 History 4 See also 5 References Contraindicatio...

Read more Selexipag Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selexipag

Recent Selexipag Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Selexipag
  • Tablet: 0.2mg, 0.4mg, 0.6mg, 0.8mg, 1.2mg, 1.4mg, 1.6mg, 1000mcg, 1200mcg, 1400mcg, 1600mcg, 1mg, 200mcg, 400mcg, 600mcg, 800mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Selexipag: (1 result)

Sorted by National Drug Code
  • 66215-628 Uptravi Titration Pack Kit by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Selexipag or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA